Table 1.
NE (n = 24) | PHI (n = 10) | CHI (n = 14) | 3ART (n = 21) | PR (n = 27) | CO (n = 21) | HC (n = 23) | |
---|---|---|---|---|---|---|---|
Gender | m = 20/f = 4 | m = 9/f = 1 | m = 11/f = 3 | m = 18/f = 3 | m = 21/f = 6 | m = 13/f = 8 | m = 9/f = 14 |
Age at blood draw (years) | 48 (24–62) | 47.5 (24–56) | 49.5 (36–62) | 49 (30–71) | 40 (20–60) | 39 (23–66) | 45 (25–62) |
CD4 pre-ART (abs., %) | 434 (212–751) 16.5% (7–37) |
467 (339–751) 23.5% (7–37) |
247 (212–489) 13.5% (8–23) |
294 (12–492) 19% (1–35) |
n.a. | n.a. | n.a. |
CD4 at blood draw (abs., %) | 713 (551–1,342) 37% (19–57) |
892 (557–1,342) 42.5% (37–57) |
676 (551–1,052) 31% (19–50) |
604 (104–1,243) 31% (9–56) |
136 (25–357) 11.5% (1–26) |
706 (467–1,442) 35% (16–48) |
n.a. |
CD4 nadir (abs.) | 360 (212–751) | 467 (339–751) | 237 (212–530) | 235 (6–472) | 143 (12–357) | 534 (270–1,259) | n.a. |
VL pre-ART (cp/ml) | 299,230 (6,769–39,791,860) | 1,410,751 (33,873–39,791,860) | 173,642 (6,769–501,187) | 40,749 (2,583–758,578) | n.a. | n.a. | n.a. |
VL at blood draw (cp/ml) | <40 (<40–150) | <40 (<40–150) | <40 (<40) | <40 (<40) | 123,818 (2,100–2,970,000) | 103 (<40–1,214) | n.a. |
Treatment length (years) | 5.5 (4.5–6.5) (=only intensified ART) | 6 (5–6.5) | 5.5 (4.5–6.5) Total years of ART: 11 (9.5–16.5) |
10.5 (4–18.5) | n.a. | n.a. | n.a. |
NE, patients in the New Era study; PHI, subgroup of the NE patients with primary HIV infection (4 patients of Fiebig stage 3; 6 patients of Fiebig stage 4); CHI, subgroup of the NE patients with chronic HIV infection; HC, HIV-uninfected controls; CO, controllers; PR, progressors; 3ART, patients treated with a conventional 3-drug ART; m, male; f, female; n.a., not applicable; abs., absolute; ART, antiretroviral therapy.
The data are presented as the median and range.
For the subgroup PHI: the CD4 count pre-ART and CD4 nadir are the same, since there was only one blood draw after the diagnosis of HIV infection and before the start of ART.
For viral load: the limit of detection was 40 cp/ml in this study.
The CD4 counts between the NE and 3ART patients at blood draw were significantly different (p = 0.044; Mann–Whitney U test). However, there was no difference in the CD4 count at blood draw between the CHI and 3ART patients (p = 0.288, Mann–Whitney U test). Therefore, the difference was driven by the PHI patients who had higher CD4 counts.